Diligence memo · auto-generated · as of July 2, 2026
GIO Blood Ltd
GIO Blood Ltd looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
GIO Blood Ltd operates in Other Health Care, based in LONDON.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
GIO Blood Ltd has raised $27M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $50M on 2023-10-04.
Most recent recorded round closed around 2022-01-21.
Valuation (modeled)modeled
Provath models GIO Blood Ltd at approximately $375M (range $64M–$1.1B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.47× the median modeled value of Series B Other Health Care companies in 2022–2024 (91 peers) — value vs value, same stage and era. Issuer reports no revenue, yet is modeled well above niche peers.
Financing rhythm & timingmixed
Historic cadence: a new round about every 20 months.
Last raise 4.4 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 87% of Other Health Care peers (5377 compared).
Modeled value ranks above 92% of those peers.
Closest niche peers: Code Biotherapeutics, Inc., Candesant Biomedical, Inc., Artis Holdings, LLC, Clarapath, Inc., Diality Inc.
Peoplefiled
1 named person on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.